- Advanced search
- Immuno Portal
- Malaria Portal
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Approved drug?||Yes (FDA & EMA (2018))|
|International Nonproprietary Names|
|Aimovig® | AMG 334 | AMG-334 | erenumab-aooe|
|Erenumab (erenumab-aooe, AMG-334) is a first-in-class monoclonal antibody targeting the calcitonin gene-related peptide receptor (CGRPR)  (and the first approved GPCR targeted monoclonal). Antibody production was initiated by immunising mice with polypeptides from the N-terminal extracellular domains of human CRLR and human RAMP1, which are subunits of the CGRPR protein complex. Erenumab (a fully human monoclonal) is being a preventative treatment for adults suffering from migraine headache.
Anti-CGRPR antagonistic monoclonals are being developed in place of non-peptide small molecule CGRPR antagonists as these have suffered from hepatotoxicity liability when tested as migraine prophylactics. Antibodies have the positive attributes of being able to span the relatively large binding domain across the CGRPR complex to provide effective blockade, offer the potential for selectivity given the similarity with other receptors in the family, and exhibit a prolonged serum half-life which facilitates longer dosing intervals .
|GtoPdb PubChem SID||315661325|
|Search PubMed clinical trials||erenumab|
|Search PubMed titles||erenumab|
|Search PubMed titles/abstracts||erenumab|